Welcome to
George Medicines
Multiple drugs are increasingly being prescribed to adequately control conditions such as hypertension, cardiovascular disease and type 2 diabetes. This can be complicated for patients and costly for health systems. At George Medicines we are using our drug development expertise and the latest formulation approaches to combine existing medicines into novel single-pill therapies with the potential to bring significant improvements in clinical outcomes and adherence.
About Us
George Medicines is a venture-backed spin-out company from George Health, initially established to commercialise the research of The George Institute for Global Health, one of the world’s leading health research institutes. Learn more about the Institute in its latest Annual Report.
We use the research base and scientific expertise of The George Institute to pursue the late-stage development of our single-pill combination therapies. We also use the commercial expertise of George Health and the infrastructure of George Clinical, the global clinical research organisation, for the formulation and clinical development of our portfolio.
We are backed by leading life sciences venture capital firm Brandon Capital, whose expertise is directed toward supporting its portfolio companies along the path to commercialisation and Brandon BioCatalyst, the largest life sciences investment fund in Australia and New Zealand.
Our Approach
George Medicines is a venture-backed spin-out company from The George Institute for Global Health, one of the world’s leading medical research institutes in non-communicable diseases. Our differentiated business model avoids the early, high-risk stages of drug discovery and development by formulating established drugs into innovative, single-pill combinations using proprietary technology, which reduces time-to-market and brings a higher probability of success while requiring less capital investment than is usual in the industry.
Pipeline
We are building a strong and diversified proprietary pipeline of innovative single-pill combination therapies, targeting some of the leading causes of death in both developed and developing countries, including hypertension, recurrent intracerebral haemorrhage (stroke), cardiovascular disease and type 2 diabetes.
Partners
Our strategy is to advance our late-stage pipeline through the final stages of development and to secure approval from global regulators. We work alongside appropriate partners to commercialise our therapies across the developed and developing world where our medicines can reduce the burden on health systems and have the biggest positive social impact.
Latest News
Chairman’s Statement
“George Medicines is uniquely positioned to change the lives of the more than 2 billion people around the world suffering from non-communicable diseases with our novel single-pill therapies. By targeting underserved populations in established and emerging markets, we are making better medicines for all. And never was it more urgent, as the pandemic has highlighted weaknesses and inequalities in health systems globally”
Part of a mission to deliver affordable and scalable treatments and technologies
George Medicines is one of George Health’s four businesses, created to commercialise medicines and technologies that leverage the George Institute’s late-stage clinical research for chronic disease.
VIEW WEBSITE +
George
Health
Science, service, solutions. A leading CRO in Asia-Pacific with global capabilities
George
Clinical
Science, service, solutions. A leading CRO in Asia-Pacific with global capabilities
